AI4Eyes Medical Technologies has secured a combined C$6.5 million in new capital to support the development and commercialization of regulated, AI-powered eye care solutions, the company said.
The total includes a C$3.7 million internal financing round from existing investors, completed in the fourth quarter of 2025, alongside C$2.8 million in non-dilutive funding. AI4Eyes said the financing improves the company’s financial position and strengthens its balance sheet as it advances its commercialization roadmap.
AI4Eyes positioned the raise as a transition point from building and validating its technology to executing on regulatory and go-to-market priorities. The company said it plans to accelerate regulatory approval activities in both Canada and the United States—work that can include expanding documentation and quality processes, completing required testing, and generating the clinical evidence needed to support clearances for AI-driven software used in care settings.
In parallel, AI4Eyes said it will continue advancing product development as it prepares offerings for deployment in real-world eye care environments. While the company did not disclose additional technical details about specific products, it emphasized “regulated” solutions, signaling a focus on systems intended for clinical use rather than consumer-only tools.
The company also plans to expand data collection and clinical trials, which it described as central to strengthening performance, safety, and reliability as it moves toward broader clinical adoption. In AI-driven healthcare, broader, more diverse datasets are often used to support validation across patient populations and care settings, and AI4Eyes indicated it will continue investing in this foundation.
Beyond development and regulatory milestones, AI4Eyes said the funding will support commercialization readiness and strategic partnerships across key global markets. The company also highlighted plans to onboard a global expert leadership team, suggesting an emphasis on operational scale-up as it progresses from product readiness into market execution.
KEY QUOTES:
“This financing marks a pivotal milestone for AI4Eyes as we shift into full-scale execution and commercialization. With the continued support of our existing investors and access to non-dilutive funding, we are accelerating regulatory approvals, expand our clinical programs, and bring meaningful AI-driven innovation to eye care providers and patients globally.”
Dr. Tara Akhavan, CEO, AI4Eyes
